Background
Methods
Patient characterization and classification
Patients included
GENE SET | SIZE | ES | NES | NOM P-VALUE |
---|---|---|---|---|
Signal sequence binding | 21 | −0.62 | −1.85 | <0.01 |
Olfactory bulb interneuron development | 10 | −0.72 | −1.77 | <0.01 |
Negative regulation of MAPK cascade | 38 | −0.5 | −1.76 | <0.01 |
Response to ionizing radiation | 85 | −0.45 | −1.69 | <0.01 |
Zinc ion transport | 16 | −0.67 | −1.76 | 0.01 |
Pre-mRNA binding | 13 | −0.7 | −1.73 | 0.01 |
Positive regulation of oxidoreductase activity | 14 | −0.65 | −1.73 | 0.01 |
Inactivation of MAPK activity | 27 | −0.48 | −1.62 | 0.01 |
Regulation of interferon-gamma biosynthetic process | 16 | −0.6 | −1.61 | 0.01 |
Carboxylic acid catabolic process | 34 | −0.45 | −1.61 | 0.01 |
Response to radiation | 189 | −0.37 | −1.56 | 0.01 |
Negative regulation of reactive oxygen species metabolic process | 11 | −0.64 | −1.68 | 0.02 |
Regulation of bone resorption | 10 | −0.7 | −1.66 | 0.02 |
RNA polymerase II transcription factor binding transcription factor activity involved in negative regulation of transcription | 11 | −0.62 | −1.65 | 0.02 |
Biotin metabolic process | 10 | −0.73 | −1.65 | 0.02 |
Regulation of isotype switching | 20 | −0.55 | −1.64 | 0.02 |
Fucosyltransferase activity | 14 | −0.64 | −1.65 | 0.03 |
Microtubule bundle formation | 24 | −0.52 | −1.6 | 0.03 |
Negative regulation of JNK cascade | 22 | −0.59 | −1.59 | 0.03 |
UV protection | 11 | −0.6 | −1.56 | 0.03 |
MutSalpha complex binding | 11 | −0.72 | −1.59 | 0.04 |
Aminopeptidase activity | 34 | −0.47 | −1.58 | 0.04 |
Mismatch repair complex | 10 | −0.74 | −1.57 | 0.04 |
Negative regulation of transcription by competitive promoter binding | 10 | −0.61 | −1.56 | 0.04 |
Cholesterol efflux | 25 | −0.51 | −1.55 | 0.04 |
Negative regulation of cytoskeleton organization | 51 | −0.41 | −1.51 | 0.04 |
Regulation of protein localization to cell surface | 17 | −0.53 | −1.51 | 0.04 |
Response to gamma radiation | 32 | −0.44 | −1.47 | 0.04 |
Treatment
Response criteria
Cell preparation
Mutation profiling
RNA preparation, labelling and microarray hybridization
Preprocessing, normalization and annotations of microarray data
Results
Classification of patients as responders and non-responders to ATRA/valproic acid
Responsiveness to AML-stabilizing therapy was not significantly associated with karyotype or the mutational profile
The gene expression profiles of responders and non-responders to AML-stabilizing treatment differ especially for genes important in nucleic acid binding, intracellular transport, function of hydrolases and modulation of enzyme activity
The effect of in vivo ATRA therapy on the global gene expression profile of primary human AML cells
Nucleic acid binding transcription factor | Hydrolases | Enzyme modulation | Receptors | |||||
---|---|---|---|---|---|---|---|---|
Increased* | Decreased | Increased | Decreased | Increased | Decreased | Increased | Decreased | |
AGAP3
|
AARSD1
|
MBTD1
|
ACP22
|
APOBEC3H
|
AGAP3
|
ARL16
|
OLFM4*
|
ADRA2C
|
ARAP3
|
APOBEC3H
|
MCART1
|
AFMID
|
ATP2A2
|
ARAP3
|
BIRC3
|
ST7
|
HP*
|
LMO4
|
ARAP3
|
MRPS15
|
LTF*
|
CDC14A
|
FBXO8
|
GNB4
|
TACSTD2*
|
MCHR2
|
NLRX1
|
DDX5I
|
MYCBP2
|
RNASE4
|
ELANE
|
MCF2L2
|
HP*
|
QRFPR
| |
PCBP2
|
CDKN2AIP
|
PBX3
|
GNB4
|
PCBP2
|
MCYBP2
|
THADA
| ||
RBMI5
|
DDX51
|
PHAX
|
HP*
|
PI3
|
MYO3B
|
XPO1
| ||
RNASE4
|
FOXP1
|
SMC4
|
LRAP
|
RGL4*
|
PHKB
| |||
RPL30
|
HIST2H2AC
|
SNRNP70
|
SMC4
|
RNASE4
| ||||
SNRPB
|
HOXA3*
|
TDRD1
|
TDP1
|
TP53BP2
| ||||
TAF8
|
HOXA4
|
THOC
|
XRCC2
| |||||
UBL4A
|
HOXA5*
|
XRCC2
| ||||||
WRN
|
LCOR
|
ZMAT3
| ||||||
LRRF1P1
|
ZNF394
| |||||||
MBD2
|
Comparison (Number of genes included in the comparison) | Nucleic acid binding transcription factor | Hydrolases | Enzyme Modulation | Receptors | ||||
---|---|---|---|---|---|---|---|---|
Increased | Decreased | Increased | Decreased | Increased | Decreased | Increased | Decreased | |
Day 1 versus day 3a
|
FOXB1
JRKL
|
SALL3
|
ETHE1
|
RBP1
KIAA244
|
GRM1
IGFALS
PTCHD1
| |||
Day 3 versus day 8b
|
RSPH9
SIRT6
ONECUT
|
SIRT6
|
KLK1
|
ITI4
ANGBL3
|
KLK1
GNG12
|
AVPR1B
|
HS.344170
KLK1
AVPR1B
GALR2
| |
Day 1 versus day 8c
|
NR2F1
PRDM13
|
ZBTB7C
|
CCNE2
|
SIPA1L1
DYNLL2
ITIH3
|
MRGPRX4
HCRTR1
UNC5B
GPR151
|
GRM1
AVPR1A
LRRC55
|